U.S. flag

An official website of the United States government

GTR Home > Conditions/Phenotypes > Hydatidiform mole, recurrent, 1

Summary

Hydatidiform moles are not naturally discharged from the body and must be surgically removed, typically by the end of the first trimester. After removal, there is up to a 20 percent risk that any tissue left behind will continue to grow and become a cancerous (malignant) tumor called a persistent mole. If the tumor invades the surrounding tissue of the uterus, it is called an invasive mole. In rare cases, this malignant tumor can transform into a different form of cancer called gestational choriocarcinoma that can spread (metastasize) to other tissues such as the liver, lungs, or brain.\n\nThe first symptom of a hydatidiform mole is often vaginal bleeding in the first trimester of pregnancy. During an ultrasound examination, the abnormal placenta appears as numerous small sacs, often described as resembling a bunch of grapes.\n\nRecurrent hydatidiform mole is a condition that affects women and is characterized by the occurrence of at least two abnormal pregnancies that result in the formation of hydatidiform moles. A hydatidiform mole is a mass that forms early in pregnancy and is made up of cells from an abnormally developed embryo and placenta. Normally, the embryo would develop into a fetus and the placenta would grow to provide nutrients to the growing fetus. When a hydatidiform mole occurs once, it is known as sporadic hydatidiform mole; if it happens again, the condition is known as recurrent hydatidiform mole. [from MedlinePlus Genetics]

Available tests

11 tests are in the database for this condition.

Genes See tests for all associated and related genes

  • Also known as: CLR19.4, HYDM, NALP7, NOD12, PAN7, PYPAF3, NLRP7
    Summary: NLR family pyrin domain containing 7

Clinical features

Help

Show allHide all

Suggested reading

  • Nguyen and Slim, 2014
    Genetics and Epigenetics of Recurrent Hydatidiform Moles: Basic Science and Genetic Counselling

Practice guidelines

  • NCCN, 2022
    NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesĀ®) Gestational Trophoblastic Neoplasia, 2022

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.